Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.94 USD | -0.95% | +8.00% | -30.89% |
May. 09 | Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating | MT |
May. 09 | Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.89% | 144M | |
+9.46% | 115B | |
+12.76% | 107B | |
-13.38% | 22.31B | |
-3.44% | 21.6B | |
-5.26% | 18.23B | |
-38.57% | 17.62B | |
+7.46% | 14.26B | |
+35.22% | 12.37B | |
-26.46% | 8.28B |
- Stock Market
- Equities
- MCRB Stock
- News Seres Therapeutics, Inc.
- Transcript : Seres Therapeutics, Inc. - Special Call